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Introduction
Huntington’s disease (HD) is an incurable neurodegenerative dis-
ease caused by more than 36 CAG repeats within the HTT gene 
(1). In HD and other polyglutamine disorders, CAG repeat expan-
sion leads to an elongated polyglutamine fragment in the encoded 
protein. Pathogenesis has been traditionally linked to abnormal 
function of the mutant protein that, through misfolding and aggre-
gation, promotes aberrant interactions with other proteins (2–4). 
The mutant protein promotes proteome disruption and alterations 
in neurotransmitter release, mitochondrial function, and tran-
scriptional activity, among other mechanisms (4).
The most recent advances in understanding HD pathogene-
sis have revealed the coexistence of mutant protein toxicity and 
detrimental activity of mutant/expanded CAG RNAs (5–9). Long 
CAG-trinucleotide repeats form RNA stable hairpin structures (10), 
with the stem portion presenting protein-binding properties (8, 
11). Abnormal interaction of specific proteins with expanded CAG 
repeats results in alterations of the normal function of these pro-
teins and consequent perturbations in gene expression and alterna-
tive splicing (8, 12). In addition, hairpin-like structures in mutant/
expanded transcripts undergo repeat-associated non-ATG (RAN) 
translation (13), which adds complexity to our understanding of the 
pathogenic processes in trinucleotide repeat expansion diseases.
An important question that has not been thoroughly addressed 
in HD and other polyglutamine diseases is the relative contribu-
tion of the full-length protein and/or the RNA-dependent mech-
anisms underlying disease pathogenesis. The elucidation of this 
question has potentially important translational implications.
Blocking or inhibiting the mutant HTT allele is an entic-
ing therapeutic strategy, and several types of modified anti-
sense oligonucleotides (ASOs) targeting the CAG tract take 
advantage of differences in the CAG repeat size between the 
normal and expanded alleles to selectively inhibit mutant HTT 
expression (14, 15). Locked nucleic acid–modified (LNA-mod-
ified) ASOs (LNA-ASOs) complementary to the CAG repeats 
have been found to block RNA translation to a variable extent, 
depending on the type of LNA-ASO (16–18). We have previous-
ly shown that a particular type of LNA-ASO with CTG repeats 
(LNA-CTG) abrogates the toxicity produced by CAG repeat 
small RNAs (sRNAs) generated from mutant HTT transcripts in 
a human neuronal cell model (9). However, the effect of LNA-
CTGs in vivo has not been examined.
Here, we have characterized the effect of LNA-CTGs on HTT 
expression and assessed whether their injection into the striatum 
of the R6/2 mouse model of HD affects motor symptoms. Our 
data show that LNA-CTGs dramatically improve motor deficits in 
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Increasing LNA-CTG concentrations resulted in progres-
sively decreased detection of both the mutant (e1_Mut) and WT 
(e1_WT) alleles by PCR when using the HTT_e1* set of primers, 
which span the CAG repeat within the HTT exon 1 transgene 
(HTT-e1) (Figure 1A and Methods). The blockage of HTT-e1 
amplification preferentially affected the mutant allele, produc-
ing a 6-fold reduction at the highest LNA-CTG dose (20 nM) 
(Figure 1B). Quantitative PCR (qPCR) with primers outside 
the CAG repeat revealed no changes in HTT mRNA levels. In 
addition, HTT transcripts and protein levels were not altered 
at 15-nM doses of LNA-CTG, which strongly inhibited HTT-e1 
amplification for up to 7 days after transfection of LNA-CTG 
(Figure 1, C and D), suggesting that LNA-CTG binding pre-
vents CAG repeat availability but does not result in RNA or 
protein degradation. These results are consistent with previous 
observations showing a weak inhibition of mutant HTT protein 
R6/2 mice and block RNA-associated detrimental pathways, with-
out significantly affecting mutant HTT levels. The present results 
pose a challenging question about the type of molecular mecha-
nisms underlying HD pathogenesis.
Results
To characterize the effects of LNA-CTGs in human full-length 
HTT, we transfected either LNA-CTG or the analogous scrambled 
control LNA-ASO (LNA-SCB) into HD fibroblasts and monitored 
LNA-CTG binding to the CAG repeat as well as HTT expression 
levels (mRNA and protein) (Figure 1). LNA-CTG binding to HTT 
mRNA was determined by the lack of PCR amplification with-
in the LNA-bound region due to the strong incompatibility of 
LNA-CTG:CAG duplexes with retrotranscription and subsequent 
PCR amplification (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI83185DS1).
Figure 1. LNA-CTG preferentially binds to expanded HTT mRNA in HD fibroblasts, without inhibiting HTT protein levels. (A) Scheme showing the 
binding sites of the primers used for PCR amplification in HTT exon 1 (HTT_e1* and HTT_e1 sets of primers) and HTT exons 29-30 (HTT_e29-30 set 
of primers). The black line represents introns. (B) HTT expression in HD fibroblasts (44_CAG repeats) transfected with different concentrations of 
LNA-CTG or LNA-SCB, 48 hours after transfection. Graph shows the RQ of HTT using the primer set HTT-e1* detecting WT (HTT-e1*-WT) or mutant 
(HTT-e1*-Mut) HTT-exon 1 and the primer set HTT_e29-30 detecting HTT-e29-30. Densitometric determinations were normalized to the β-actin PCR 
product and referred to the mock-transfected condition with a value of 1. Results are expressed as the mean ± SEM (n = 6). Box plot shows quartile 
values of the RQ of WT versus mutant HTT-e1* mRNA levels normalized to β-actin levels in HD fibroblasts transfected with LNA-CTG or LNA-SCB. 
A representative gel electrophoresis of the PCR products is shown. *P < 0.05, by Mann-Whitney U test with Bonferroni’s correction for multiple 
comparisons (n = 6 independent transfections). (C) HTT expression at different time points after transfection with 15 nM LNA-ASOs in HD fibroblasts 
(68_CAG repeats). The mean determinations ± SEM of HTT-e1*-WT and HTT-e1*-Mut and HTT-e29-30 relative to β-actin PCR products and a repre-
sentative PCR gel electrophoresis are shown (n = 3). (D) Dot plots show Western blot densitometric analysis of WT HTT (WT-HTT) versus mutant HTT 
(mHTT) protein levels and total HTT (WT and mutant alleles) protein levels normalized to β-actin and expressed relative to an LNA-SCB–transfected 
sample with a value of 1. A representative immunoblot is shown (n = 3).
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erential binding to the CAG repeats in expanded HTT mRNA and 
that this binding is compatible with HTT translation. Thus, LNA-
CTGs are an optimal tool for dissecting the effects of expanded 
CAG repeat blockage that are not necessarily linked to inhibition 
of HTT expression.
To evaluate the effect of LNA-CTG on HD in vivo, we used 
the R6/2 HD mouse model that expresses a human HTT-e1 with 
90 CAG repeats. WT and R6/2 mice were assessed with the 
rotarod task from 5 weeks of age to evaluate motor coordina-
tion (Supplemental Figure 5A). The mice received 2 consecutive 
intrastriatal injections of LNA-CTG or control LNA-SCB at 11 
weeks of age, when motor symptoms appeared in the R6/2 mice 
(Figure 2A). Deficits in motor coordination in the R6/2 mice were 
expression by some types of LNA-ASOs complementary to the 
CAG repeats, when used at similar concentrations (17).
At the 15-nM dose, we found reduced nuclear foci in HD 
fibroblasts when using a fluorescent ISH probe targeting the CAG 
repeats. This result provides additional evidence for the direct 
binding between LNA-CTG and the mutant HTT transcript (Sup-
plemental Figure 2).
Additional experiments using a human neuronal cell model 
expressing HTT-e1 confirmed a preferential binding of LNA-CTG 
for expanded HTT-e1 RNA (Supplemental Figure 3), while protein 
levels remained unaffected by LNA-CTG administration (Sup-
plemental Figure 4A). Collectively, these data indicate that LNA-
CTG can be used at concentrations that show efficient and pref-
Figure 2. Intrastriatal injection of LNA-CTG induces rapid motor improvement in the R6/2 mouse model of HD, without affecting WT or mutant HTT 
expression levels. (A) Schematic representation of pharmacological treatment administered and analyses. (B) Results from the rotarod test performed at 
16, 24, and 32 rpm by mice between 5 and 15 weeks of age. Values represent the number of falls within 60 seconds as the mean ± SEM (WT n = 16; R6/2  
n = 23; after surgery: WT n = 11; R6/2 LNA-SCB n = 11; R6/2 LNA-CTG n = 12). ***P < 0.001 versus WT vehicle-treated mice, as determined by 2-way ANOVA 
with Bonferroni’s post-hoc correction. (C) WT HTT (WT-HTT) and mutant HTT-e1 (mHTT) protein levels in the striatum of WT and R6/2 mice following intras-
triatal injection of LNA-SCB or LNA-CTG, as analyzed by Western blotting. Box plots show the percentage of HTT and mHTT in the striatum of WT and/or R6/2 
mice at different time points after LNA-ASO injection. Densitometric HTT and mHTT determinations were normalized using α-tubulin as an endogenous con-
trol and expressed as a percentage of a WT or R6/2 sample. Representative immunoblots are shown. WT: LNA-SCB–injected WT mice; sR6: LNA-SCB–injected 
R6/2 mice; aR6/2: LNA-CTG–injected R6/2 mice. Data were analyzed with Kruskal-Wallis (WT-HTT) and Mann-Whitney U (mHTT) tests (n = 4–12 animals per 
group). (D) HTT-e1 RNA transgene expression was analyzed by RT-PCR using the primer sets HTT_e1* or HTT_e1. Representative PCR products from animals 
injected with LNA-CTG or LNA-SCB are shown. β-Actin and Gdx amplification was used for internal controls. Box plots show RQ (obtained by densitometry) of 
HTT-e1 PCR products normalized to β-actin levels and referred to a control R6/2 LNA-SCB sample with a value of 1. *P < 0.01, when comparing LNA-SCB versus 
LNA-CTG–injected R6/2 mice in HTT_e1* PCR amplifications; Mann-Whitney U test with Bonferroni’s correction (n = 5–8 mice per group).
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plemental Figure 11). Among the microarray probes that detected 
strong downregulation, we observed a significant enrichment in 
those that contained at least 4 consecutive CAG repeats (Table 1). 
For these genes, qPCR validation suggested that downregulation 
probably reflected an interference of LNA-CTG with retrotrans-
cription during the process of sample preparation for microarray 
hybridization, rather than a true decrease in expression (Figure 
3 and Table 1). Additional genes containing a short CAG repeat 
stretch (Maml2, Mef2a, Nr3c1, and Satb1) that were not specif-
ically targeted by the probe in the microarray also showed an 
apparent downregulation when primers spanning the CAG repeat 
were used; however, this trend was not confirmed when primers 
outside the CAG repeat were used (Supplemental Figure 12A). In 
addition, no modifications in the corresponding protein levels 
were detected after treatment with LNA-CTG (Supplemental Fig-
ure 12B), suggesting that binding of LNA-CTG to endogenously 
expressed short CAG repeats was compatible with protein trans-
lation, as shown for the HTT gene (Figures 1 and 2).
LNA-CTG similarly bound to genes harboring short CAG 
repeats in WT mice striatum, without noticeable effects on the 
transcript levels (Supplemental Figure 13). The lack of effect of 
LNA-CTG on WT motor coordination and the rapid and sustained 
beneficial effects of LNA-CTG on R6/2 mice suggest that off-tar-
get binding to endogenously expressed short CAG repeats had no 
detrimental functional consequences at the tested dose.
In addition, we examined the protein levels of several neuro-
nal markers whose expression is strongly decreased in striatal cells 
expressing mutant HTT (20–25) (Figure 4). Treatment with LNA-
CTG resulted in a significant recovery of protein levels of the PH 
domain and leucine-rich repeat protein phosphatase 1 (PHLPP1), 
dopamine- and cyclic AMP–regulated phosphoprotein of 32 kDa 
(DARPP-32), striatal-enriched protein tyrosine phosphatase 46 
(STEP46), and postsynaptic density protein 95 (PSD95). A simi-
significantly attenuated as soon as 1 week after the first intrastri-
atal injection of LNA-CTG (i.e., at 12 weeks of age) and persist-
ed for at least 4 additional weeks (i.e., 15 weeks of age) (Figure 
2B). Injection of LNA-CTG did not produce significant changes 
in BW or muscular strength (Supplemental Figure 5, B and C). In 
contrast, WT animals treated with LNA-CTG showed no alter-
ations in their performance on the rotarod compared with WT 
mice injected with LNA-SCB (Supplemental Figure 6A), suggest-
ing that LNA-CTG specifically improved motor coordination 
performance in R6/2 mice.
Motor improvement was not linked to any changes in the 
expression of the HTT-e1 transgene or endogenous (HTT) pro-
teins or HTT-e1 mRNA at different time points after LNA-CTG 
administration (Figure 2, C and D, Supplemental Figure 6B, and 
Supplemental Figures 7–9). The lack of effect on HTT-e1 and 
endogenous HTT protein was demonstrated with MAB2166, 
EM48, and MAB5492 antibodies (Figure 2 and Supplemental 
Figure 8). However, the lack of HTT-e1 mRNA amplification with 
primers spanning the CAG repeat suggests LNA-CTG binding 
to the expanded transgene (Figure 2D and Supplemental Figure 
9), as shown in HD fibroblasts (Figure 1). Similar results were 
observed in a mouse full-length Htt context upon transfection of 
LNA-CTG into immortalized striatal neuronal cells expressing 
endogenous levels of normal and expanded HTT protein with 7 
(STHdhQ7/Q7) and 111 (STHdhQ111/Q111) glutamines, respectively (19) 
(Supplemental Figure 10).
To identify pathways underlying the beneficial effects of 
LNA-CTG, we examined overall gene expression changes in stri-
atal samples shortly before motor improvement was evident, e.g., 
5 days after the first injection. We detected a total of 56 dysreg-
ulated genes (n = 5–7 animals per group; adjusted P < 0.2, fold 
change greater than or less than 1.2) in LNA-CTG– versus LNA-
SCB–treated R6/2 mice (Table 1, Supplemental Table 1, and Sup-
Table 1. Top dysregulated genes in the microarray analysis that were validated by qPCR
Microarrays qPCR (reference gene: Hprt) qPCR (reference gene: Tbp)
Gene name Systematic name Fold change Adjusted P value Fold change P value Fold change P value >4 CAG in the 
array probe
Arhgap17 NM_144529 0.02 0.00 0.02 0.00 0.13 0.00 Yes
Pif1 A NM_172453 0.02 0.00 0.95 0.60 1.06 0.42 Yes
Crebbp NM_001025432 0.03 0.00 0.04 0.00 0.05 0.00 Yes
Trp63 NM_001127261 0.06 0.00 0.07 0.00 0.08 0.00 Yes
D130043K22Rik A NM_001081051 0.06 0.00 0.97 0.74 1.09 0.41 No
Git2 NM_019834 0.06 0.00 0.76 0.01 0.86 0.02 Yes
Pf4 NM_019932 0.12 0.10 0.26 0.00 0.29 0.00 No
Mdh2 NM_008617 0.14 0.01 0.09 0.00 0.11 0.00 Yes
Phlpp1 A NM_133821 2.33 0.16 0.94 0.56 – – No
P2ry13 A NM_028808 2.62 0.05 1.04 0.65 1.18 0.07 No
Pde3b NM_011055 2.70 0.12 1.33 0.04 1.50 0.00 No
Med1 A NM_134027 2.75 0.17 0.70 0.00 0.79 0.01 No
P2ry12 NM_027571 3.34 0.05 1.47 0.01 1.66 0.00 No
Gpr34 NM_011823 3.35 0.02 1.49 0.00 1.68 0.00 No
Two quantifications were performed using Hprt or Tbp as reference genes. The fold change is shown for R6/2 mice injected with LNA-CTG  
versus R6/2 mice injected with LNA-SCB. The last column indicates if the probe in the microarray contained at least 4 consecutive CAG repeats.  
AGene was not validated by qPCR. 
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in R6/2 mice receiving LNA-CTG. Dicer activity on the hair-
pin-like double-stranded structure in expanded CAG repeats of 
HTT-e1 results in the biogenesis of small CAG-repeated RNAs 
(sCAGs) (26) with toxic activity (9). In addition, binding of dicer 
to expanded CAG repeats has been proposed to contribute to 
abnormal miR expression profiles that may underlie pathogenic 
alterations in gene expression (27).
To evaluate whether the detrimental effect of sRNAs was 
reversed by LNA-CTG, we isolated an sRNA-enriched fraction 
(<200 nt) from the striatum of WT and R6/2 mice injected with 
LNA-SCB and from R6/2 mice injected with LNA-CTG (pooled 
extracts from at least 11 mice per condition) and determined cell 
death after transfection into a differentiated neuronal cell line 
(Figure 5A). The sRNA fraction isolated from R6/2 mice injected 
with LNA-SCB produced a significant increase in cell death that 
was not detected upon transfection of sRNAs isolated from R6/2 
mice injected with LNA-CTG. This result suggests that LNA-CTGs 
block the sRNA pathogenic mechanisms in the mouse brain.
lar tendency was observed for CREB-binding protein (CBP) and 
enkephalin (ENK) (Figure 4A). The trend toward the recovery of 
CBP protein levels and the binding of LNA-CTG to the CAG repeats 
in the Crebbp transcript (Figure 3B) further reinforce the idea that 
LNA-CTG binding to CAG repeats does not hamper translation of 
the targeted transcript. Parallel changes in the transcripts encod-
ing for DARPP-32, ENK, STEP, and PSD95 were not detected 
according to the microarray analysis, indicating that LNA-CTGs 
posttranscriptionally modulate the expression of these genes. 
LNA-CTG did not alter the levels of these striatal markers in WT 
mice (Supplemental Figure 6B), which is in line with the specific 
effect of LNA-CTG in R6/2 mice. Immunofluorescence analysis 
of DARPP-32–positive neurons confirmed the Western blot results 
and suggested that DARPP-32 downregulation in striatal neurons 
was reversed close to the injection site (Figure 4B).
Since LNA-CTGs bind to the expanded CAG repeats in 
mutant HTT-e1 RNA, we evaluated whether pathogenic mech-
anisms directly dependent on expanded RNA were modified 
Figure 3. Downregulation of specific genes containing CAG repeats, detected by microarray analysis, reflects binding of LNA-CTG to the CAG stretch. 
(A) Schema showing the binding site of the primers spanning the CAG repeats (p1) and primers mapping outside the CAG repeats (p2). (B) The expression 
levels of Crebbp, Mdh2, and Arhgap17 are shown in WT animals injected with LNA-SCB and R6/2 mice injected with LNA-SCB or LNA-CTG. A WT sample 
was used as a reference for RQ. Quantification was normalized to Tbp or Hprt as independent reference genes. *P < 0.01 with respect to WT LNA-SCB mice; 
†P < 0.01 with respect to R6/2 LNA-SCB mice. Data were analyzed using a linear mixed-effects model and Bonferroni’s correction was applied for multiple 
comparisons (n = 5–7 mice per group).
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The pooled sRNAs transfected into cells contained enriched 
amounts of sCAG (Supplemental Figure 14). However, in the pres-
ent study sCAG molecules were moderately increased in the stria-
tum of R6/2 mice (1.22 fold change, P = 0.09) (Supplemental Fig-
ure 14), compared with the originally reported 2-fold increase (9), 
which may be related with the shorter CAG repeat length in the 
R6/2 mouse model used in this study. It remains to be determined 
whether the beneficial effect of LNA-CTG is the consequence of it 
blocking the production and activity of sCAG and/or other sRNAs.
Decreased transcription of rRNA leading to nucleolar stress 
is another detrimental mechanism directly induced by RNA 
with expanded CAG repeats, including in R6/2 mice (5, 28). 
In agreement with this, the levels of Rn45s (45S pre-ribosomal 
RNA) were significantly decreased in R6/2 mice compared with 
levels in WT mice at 16 weeks of age (Supplemental Figure 15). 
At this time point (5 weeks after injection), R6/2 mice receiving 
LNA-CTG showed strong increases in Rn45s levels compared 
with those in R6/2 and WT mice injected with LNA-SCB (Sup-
plemental Figure 15). No decreased levels of Rn45s or modifi-
cations upon LNA-CTG treatment were detected 5 days after 
injection, suggesting that Rn45s expression recovery could con-
tribute to improvement at later time points.
Overall, these data suggest that detrimental mechanisms 
directly driven by expanded CAG repeat RNA are strongly reversed 
by LNA-CTG injection into the striatum of R6/2 mice and that this 
reversal contributes to LNA-CTG–mediated motor improvement.
Figure 4. Intrastriatal injection of 
LNA-CTG recovers protein levels of 
several striatal markers in R6/2 mice. 
(A) Levels of specific neuronal proteins 
5 days after the first intrastriatal injec-
tion of LNA-SCB into WT and R6/2 
mice and LNA-CTG into R6/2 mice. 
Box plots represent the densitometric 
protein quantification normalized to 
actin or tubulin and expressed relative 
to WT mice. Representative immuno-
blots are shown. Data were analyzed 
using the Kruskal-Wallis test, provid-
ing significant differences in all cases 
(P < 0.05). To determine statistical 
post-hoc differences between pairs 
of groups, the Mann-Whitney U test 
with Bonferroni’s correction was used 
(n = 6–8). *P < 0.05 and **P < 0.01, 
compared with LNA-SCB–injected WT 
mice; †P < 0.05 and ††P < 0.01, com-
pared with LNA-SCB–injected R6/2 
mice. (B) Individual points show the 
fluorescence intensity of DARPP-32 
staining along rostral-to-caudal 
striatal sections in WT LNA-SCB, R6/2 
LNA-SCB, and R6/2 LNA-CTG mice 5 
days after the first intrastriatal injec-
tion. IOD, integrated optical density. 
ANOVA was applied using a correlation 
structure for the repeated measures 
of each animal across 8 sections (8 
repeated measures for four WT LNA-
SCB–, two R6/2 LNA-SCB–, and three 
R6/2 LNA-CTG–injected animals). 
Representative images of DARPP-32 
staining in each condition are shown. 
Scale bar: 500 μm.
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Discussion
Inhibition of mutant HTT expression has been proposed as a major 
therapeutic strategy in treating HD. Our efforts have surprising-
ly shown that blocking the activity of expanded CAG repeats in 
HTT-e1 transcripts without modifying HTT RNA or protein levels 
is sufficient to reverse motor symptoms in an HD mouse model.
Several types of LNA-ASOs complementary to the CAG 
repeats have been used for allele-selective inhibition in HD 
human fibroblasts at the protein level, with virtually no effect 
on HTT mRNA (16–18, 29). These studies showed that the con-
figuration of the LNA-ASO largely affects the efficiency of pro-
tein inhibition. LNA-ASOs formed by 6 or 7 GTC repeats with 
3′ and 5′ terminal guanines and LNA nucleotides at every third 
thymine residue strongly inhibited protein expression (16, 17). 
However, those consisting of CTG repeats were less efficient 
(17, 18), which agrees with our finding of a lack of effect of LNA-
CTG on HTT protein levels.
We have demonstrated that the lack of effect of LNA-CTG 
on HTT protein expression levels is accompanied by the efficient 
binding of LNA-CTG to the full-length HTT transcript in human 
fibroblasts and Htt-knockin mouse striatal neuronal cells. We have 
shown that LNA-CTG binding to the CAG repeats is a strong barri-
er for retrotranscription as previously suggested (18); and the con-
sequent lack of RT-PCR amplification of fragments spanning the 
CAG repeat permitted tracking of LNA-CTG binding to mutant 
HTT-e1 and other genes. The characterization of LNA-CTG dos-
age effects in HD fibroblasts indicated a preferential binding to 
the expanded allele with a 6-fold selectivity, which agrees with 
previous studies focusing on the effect of other ASOs on HTT pro-
tein expression (16, 17, 29, 30).
The therapeutic potential of HTT expression inhibition has 
been preclinically tested in rodent models by using a non-allele–
selective approach based on virally expressed small hairpin RNAs 
(31–33), siRNAs (34), and ASOs (35). In these studies, a significant 
decrease in HTT protein levels reduced neuropathological signs, 
ameliorated symptoms, and prolonged the survival of HD mice. In 
addition, allele-selective phosphorodiamidate morpholino ASOs 
targeting the CAG repeat have recently shown antidepressant 
activity in a mouse model of HD that was linked to decreased lev-
els of mutant HTT protein expression (36). In contrast, our results 
using LNA-ASOs complementary to the CAG repeats suggest that 
inhibition of mutant HTT-e1 protein expression is not necessary 
for reversing motor deficits in R6/2 mice or blocking toxicity in a 
neuronal cell model. These data, along with the lack of effect of 
Figure 5. LNA-CTGs reverse the toxicity produced by sRNAs extracted from the striatum of R6/2 mice. (A) Workflow to evaluate the toxic effect of 
sRNAs isolated from mice injected with LNA-SCB or LNA-CTG, after motor performance evaluation. (B) Differentiated SH-SY5Y cells were transfected with 
sRNAs (20 ng or 40 ng per well) from WT or R6/2 mice injected with LNA-SCB or from R6/2 mice injected with LNA-CTG, and cell death was evaluated 40 
hours later using the lactate dehydrogenase (LDH) assay. Box plot shows relative cell death in each condition referred to a control mock-transfected sam-
ple with a value of 1. *P < 0.05, by Kruskal-Wallis test, followed by a Mann-Whitney U test with Bonferroni’s correction as a post-hoc test (n = 4).
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Repeat-associated non-ATG (RAN) translation is another 
mechanism dependent on expanded CAG RNA hairpin-like struc-
tures that may contribute to HD pathogenesis (40). The possibility 
that LNA-CTG disrupts the biogenesis of RAN translation prod-
ucts needs further investigation.
LNA-CTG–mediated reversal of sRNA toxicity and recovery 
of Rn45s transcript levels suggest that these mechanisms underlie 
motor dysfunction in R6/2 mice. Accurate molecular and behav-
ioral longitudinal studies in vivo, correlating the appearance of 
motor symptoms with the detection of the above-mentioned del-
eterious outcomes in the presence and absence of LNA-CTG, will 
help to unravel the relevance of each pathogenic mechanism.
In summary, our data strongly suggest that the beneficial 
effects of LNA-CTG depend, at least in part, on the blockage of 
direct RNA detrimental effects, which has important mecha-
nistic implications in HD pathogenesis. Whether motor recov-
ery depends on additional indirect effects of LNA-CTG on HTT 
downstream targets and pathogenic pathways remains to be 
resolved. Using LNA-CTGs could help to elucidate the highly 
complex details of HD pathogenesis involving both RNA- and pro-
tein-dependent mechanisms. Finally, since targeting CAG repeats 
could be a valuable strategy for other CAG/polyglutamine disor-
ders, the results presented here could help to establish a general 
approach to treating several rare neurodegenerative disorders for 
which there is no currently cure.
Methods
Cell lines and transfection
Primary HD fibroblasts. Fibroblasts were obtained from Coriell Insti-
tute for Medical Research. Cells were maintained at 37 °C and 5% CO2 
in Eagle MEM (Gibco, Life Technologies, Thermo Fisher Scientific) 
supplemented with 12.5% heat-inactivated FBS (Sigma-Aldrich), 2 
mM L-glutamine, 100 units/ml penicillin and 100 mg/ml streptomy-
cin (Gibco, Thermo Fisher Scientific), and 50% DMEM (Sigma-Al-
drich). Fibroblasts were maintained for a maximum of 20 passages. 
We used GM04208 and GM04281 cell lines with mutant alleles carry-
ing 44_CAG or 68_CAG repeats.
SH-SY5Y neuronal cells. SH-SY5Y neuroblastoma cells (catalog 
94030304; Sigma-Aldrich) were grown in DMEM (Invitrogen, Ther-
mo Fisher Scientific) supplemented with 10% inactivated FBS, and 100 
units/ml penicillin and 100 mg/ml streptomycin (Gibco, Thermo Fisher 
Scientific). SH-SY5Y cells were differentiated with 10 mM retinoic acid 
(Sigma-Aldrich) added to the growing media, for 4 days. Media were 
removed and replaced by fresh growth media containing 80 nM 12-O-tet-
radecanoylphorbol-13-acetate (Sigma-Aldrich) for 5 additional days.
Knockin striatal cells. Conditionally immortalized WT (STHdhQ7/Q7) 
and mutant (STHdhQ111/Q111) striatal neuronal progenitor cell lines 
expressing endogenous levels of normal and mutant Htt with 7 and 
111 glutamines, respectively, have been described elsewhere (19). 
Cells were a gift of M.E. MacDonald (Massachusetts General Hos-
pital, Boston, Massachusetts, USA). Cells were grown at 37°C in 
DMEM (Gibco, Thermo Fisher Scientific) supplemented with 10% 
FBS, 1% nonessential amino acids, 2 mM L-glutamine, and 400 μg/
ml G418 (Geneticin; Invitrogen, Thermo Fisher Scientific).
Cell transfections were performed using Lipofectamine 2000 
(Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s 
morpholino ASOs on HTT mRNA levels (36), bring into question 
whether behavioral improvement is caused by protein inhibition 
and/or blockage of expanded CAG repeats at the RNA level.
In this study, we used an R6/2 HD mouse model featuring 90 
CAG repeats in the transgene, instead of the 150 CAG repeats orig-
inally described (37). The shorter CAG-repeat length translated 
into a less aggressive phenotype, with symptoms starting around 
week 11, the earliest symptomatic time point chosen for adminis-
tration of LNA-CTG. Two consecutive intrastriatal injections of 
LNA-CTG ASOs substantially improved molecular pathology and 
motor symptoms as early as 1 week after administration, effects 
that lasted at least 5 weeks. Improvement in motor symptoms 
correlated with sustained LNA-CTG binding to expanded CAG 
repeats, which agrees with the high biological stability of LNA-
ASOs with phosphorothioate-modified backbones (38). Whether 
significant recovery is feasible in older animals, in which motor 
deficits are more pronounced, remains to be determined.
LNA-CTG facilitated the partial recovery of protein levels that 
were strongly decreased in R6/2 mice. Changes in the expression 
of these proteins may reflect the rapid neuroprotective effect of 
LNA-CTG and preservation of striatal neuron function, consistent 
with LNA-CTG–mediated blockage of mutant HTT RNA toxici-
ty in a neuronal cell model and with the striking amelioration of 
motor symptoms we observed in vivo.
One of the main drawbacks to targeting the CAG repeats as a 
therapeutic strategy in HD and other polyQ disorders is the lack 
of selectivity. Although we demonstrate a preferential binding 
to expanded CAG repeats, LNA-CTGs similarly bound to other 
genes with shorter, normal CAG repeats. However, the lack of a 
noticeable effect of LNA-CTGs on the motor performance of WT 
mice and on the expression levels of the targeted genes suggests 
that off-target binding to endogenous genes does not attenuate 
normal functionality.
Our data show that LNA-CTGs, at the concentrations used in 
R6/2 mice and in different cell models, strongly bind to the CAG 
repeats in HTT-e1, without affecting transcript and protein levels. 
Thus, we propose that the beneficial activity of LNA-CTG in vivo 
may be due to its blocking the activity of the CAG repeat expansion in 
HTT-e1 RNA. In the present study, evidence suggests that LNA-CTGs 
reverse deleterious mechanisms directly dependent on an RNA toxic 
gain of function. Expanded CAG repeats form a hairpin-like second-
ary structure that causes RNA toxicity through diverse mechanisms 
involving aberrant interactions with proteins and consequent altered 
functions (12). These include dicer and nucleolin (NCL), which under-
lie deleterious sRNA expression profiles (9, 27) and decreased Rn45s 
expression levels mediating nucleolar stress (5, 28), respectively.
LNA-CTG binding to the CAG repeats may disrupt sequestra-
tion and alter the activity of dicer and NCL, leading to the rever-
sal of sRNA toxicity and recovery of Rn45s levels in R6/2 mice. 
Supporting this, a similar mechanism has been recently shown 
for LNA-ASOs targeting expanded CUG repeats in DMPK tran-
scripts, which prevented muscleblind-like splicing regulator 1 
(MBNL1) sequestration and corrected alternative splicing abnor-
malities (39). Since MBNL1 also binds to expanded CAG repeats 
(7), it remains to be determined whether analogous corrections 
in alternative splicing patterns occur in R6/2 mice injected with 
LNA-CTG, which could underlie motor improvement.
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at 2.6 mm below the dural surface with the incisor bar at 3 mm above 
the interaural line. These injections were given twice per mouse, sep-
arated by 3 days. A 10-μl Hamilton microliter syringe was used for the 
injections at an infusion rate of 0.25 μl/minute, and the needle was 
left in place for 7 minutes to ensure complete diffusion and then slow-
ly retracted from the brain. Mice were allowed to recover for 1 week 
before undergoing the rotarod and hanging wire tests.
Mice were killed by decapitation 2, 10, or 32 days after intrastriatal 
injection of LNA-SCB or LNA-CTG. Immediately after decapitation, 
brains were removed and halved sagittally. The hemispheres were 
processed for histology and protein or RNA extraction.
Total protein extraction and Western blot analysis
Cells were washed once with PBS and then incubated with lysis buf-
fer at the indicated post-transfection time points (Figure 1, B and C, 
Figure 5B, Supplemental Figure 2, Supplemental Figure 3B, Supple-
mental Figure 4, and Supplemental Figure 10). Cells and tissues were 
homogenized in lysis buffer containing 1% Triton X-100, 50 mM 
Tris-HCl (pH 7.5), 10 mM EGTA, 150 mM NaCl, protease inhibitors 
(2 mM PMSF, 10 μg/μl aprotinin, 1 μg/l leupeptin), and phosphatase 
inhibitors (2 mM Na3VO4, 100 mM NaF) and centrifuged at 16,100 ×g 
for 20 minutes at 4°C. The supernatants were collected, and protein 
concentration was measured using the DC Protein Assay Kit (Bio-
Rad). Western blot analysis was performed as previously described 
(48). The following primary antibodies were used: anti-HTT (1:1,000, 
catalog MAB2166, clone 1HU-4C8; 1:2,000, catalog MAB5492); 
anti–mutant HTT (1:1,000, catalog MAB5492, clone EM48); and anti-
polyQ (1:1,000, catalog MAB1574, clone 5TF1-1C2) from EMD Milli-
pore; anti-DARPP32 (1:1,000, catalog 611520, clone 15/DARPP-32; 
BD Biosciences); anti-ENK (1:1,000; a gift of Dr. Dickson, Depart-
ment of Emergency Medicine, University of Iowa, Iowa City, USA; 
ref. 49); anti-PHLPP1 (1:500, catalog 10007191; Cayman Chemical); 
anti-STEP (1:1,000, catalog sc-23892, clone 23E5; Santa Cruz Bio-
technology Inc.); anti–PSD-95/SAP-90 (1:1,000, catalog MA1-046, 
clone 7E3-1B8; Thermo Fisher Scientific); anti-MAML2 (1:1,000, 
catalog 6988, clone D41E6; Cell Signaling Technology); anti- MEF2A 
(1:1,000, catalog 9736; Cell Signaling Technology); anti-SATB1 
(1:1,000, catalog ab7004; Abcam); and anti-GR/NR3C1 (1:1,000, 
catalog NB300-731, clone BuGR2; Novus Biologicals). The loading 
control was performed by reprobing the membranes with an anti–α- 
tubulin antibody (1:50,000, catalog T9026, clone DM1A; Sigma- 
Aldrich) for 20 minutes at room temperature. Then, membranes were 
washed with Tris-buffered saline containing 0.1% Tween-20 (TBS-T), 
incubated for 1 hour at room temperature with the corresponding 
HRP-conjugated antibody (1:2,000, anti-mouse IgG [H+L], catalog 
W402B and anti-rabbit IgG [H+L], W401B; both from Promega), and 
washed again with TBS-T. Immunoreactive bands were visualized 
using the Western Blotting Luminol Reagent (Santa Cruz Biotechnolo-
gy Inc.) and quantified by a computer-assisted densitometer (Gel-Pro 
Analyzer, version 4; Media Cybernetics).
IHC and morphological analysis in mouse brains
Cerebral hemispheres were fixed by immersion in 4% paraformal-
dehyde solution in 0.1 M sodium phosphate, pH 7.2, for 3 days. Tis-
sues were then cryoprotected by immersion for 24 hours in 10%, 
20%, and 30% sucrose in PBS with 0.02% sodium azide and frozen 
in dry ice–cooled 2-methylbutane. Serial coronal sections (30-μm 
instructions and at a cell confluence of 60%. Vectors expressing WT or 
mutant HTT-e1 (9) were transfected using concentrations between 0.6 
ng/μl and 0.3 ng/μl. sRNAs were transfected in 2 different amounts 
(20 and 40 nmol per well). LNA-ASOs were transfected at the dosages 
indicated in the figure legends. The LNA-ASO complementary to the 
CAG repeat (LNA-CTG) consisted of a 20-nt length oligonucleotide, 
CTGCTGCTGCTGCTGCTGCT, with LNA located every third T and 
a phosphorothioate-modified backbone. LNA-CTG and the control 
scrambled LNA-modified sequence (LNA-SCB) 5′-GTGTAACAC-
GTCTATACGCCCA-3′ were obtained from Exiqon. Lipofectamine 
alone was used for control (mock-transfected) cells.
HD mouse model
For this study, we used male WT and R6/2 transgenic mice (B6CBA 
background) expressing a human mutant HTT exon 1 with 90 CAG 
repeats instead of the 150 repeats originally described (37). Orig-
inal R6/2 mice were purchased from The Jackson Laboratory. Colo-
ny maintenance resulted in a decrease of the CAG repeat length, in 
agreement with CAG repeat instability as previously described by 
other groups (41–43). Mouse genotype was determined as previously 
described (44). CAG repeat length was determined by PCR amplifi-
cation of the repeat using HD1 and HD2 fluorescently labeled prim-
ers (45) and subsequent size determination in an ABI 3100 analyzer 
(Applied Biosystems). These results were further validated by Laragen 
Inc. All mice were housed together in numerical birth order in groups 
of mixed genotypes, and data were recorded for analysis by microchip 
mouse number. The animals were housed with ad libitum access to 
food and water in a colony room kept at 19°C to 22°C and 40%–60% 
humidity, under a 12-hour light/12-hour dark cycle.
Behavioral analysis
Rotarod. Motor coordination and balance were evaluated on the rotarod 
apparatus at distinct rotations per minute (rpm), as described elsewhere 
(46). Animals were trained at a constant speed (24 rpm) for 60 seconds 
at 4 or 8 weeks of age. We performed 2 trials per day for 3 consecutive 
days, and the number of falls during 60 seconds was recorded. No dif-
ferences between groups were detected during this period. After train-
ing, animals were evaluated once a week at 16, 24, and 32 rpm, and the 
number of falls in a total of 60 seconds was recorded. The animals were 
put on the rotarod several times until the addition of the latency to fall-
off reached a total of 60 seconds. The curves representing the behavioral 
pattern were compared, and the percentage of motor coordination func-
tion impairment was calculated as described elsewhere (47).
Hanging wire. Neuromuscular abnormalities were analyzed by the 
hanging wire test as described elsewhere (46), beginning 1 week after 
surgery. A standard wire cage lid was used. To test balance and grip 
strength, mice were placed on top of a wire cage lid. The lid was shak-
en slightly to cause the mouse to grip the wires and then turned upside 
down for 60 seconds. The latency to fall was recorded.
Intrastriatal injection
Eleven-week-old WT and R6/2 mice were deeply anesthetized with 
pentobarbital (50 mg/kg) and placed in a stereotaxic apparatus for a 
bilateral injection into the striatum. Then, 2 μl of 25 μM LNA-SCB or 
LNA-CTG (final amount, 0.05 nmols) was injected at 2 different coor-
dinates relative to bregma: (a) anteroposterior (AP) +0.3 mm; medio-
lateral (ML) ± 2 mm; and (b) AP + 0.8 mm; ML ± 1.8 mm; in both cases 
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Thermo Fisher Scientific). HTT-e1 RNA was used to evaluate retrotran-
scription performance in the presence of bound LNA-ASOs. HTT-e1 
RNA was first incubated with either LNA-CTG or LNA-SCB at a molar 
ratio of 1:5 (HTT-e1/LNA-ASOs) at 37°C for 1 hour. Retrotranscription 
was then performed with the SuperScript III First-Strand Synthesis Sys-
tem (Invitrogen), using a sequence-specific primer (see Supplemental 
Table 1 for primer descriptions). Retrotranscription products were 
resolved by denaturing polyacrylamide gel electrophoresis.
Microarray hybridization and analysis
Total RNA (100 ng) was labeled using the Low Input Quick Amp 
Labeling Kit (Agilent Technologies) following the manufacturer’s 
instructions. Briefly, mRNA was reverse transcribed in the presence 
of T7-oligo-dT primer to produce cDNA, which was then in vitro tran-
scribed with T7 RNA polymerase in the presence of Cy3-CTP to pro-
duce labeled cRNA. The labeled cRNA was hybridized to the Agilent 
SurePrint G3 Mouse GE 8 × 60K Microarray according to the manu-
facturer’s protocol. The arrays were washed and scanned on an Agilent 
G2565CA microarray scanner at 100% photomultiplier tube (PMT) 
and 3 μm resolution. Intensity data were extracted using the Agilent 
Feature Extraction software.
Raw data were taken from the Feature Extraction output files 
and corrected for background noise using the normexp method (51) 
(Gene Expression Omnibus [GEO] accession number GSE85126). To 
assure comparability across samples, we used quantile normalization 
(52). Differential expression analysis was carried out on noncontrol 
probes with an empirical Bayesian approach on linear models (limma) 
(53). Results were corrected for multiple testing according to the FDR 
method (54). All statistical analyses were performed using Bioconduc-
tor software (http://www.bioconductor.org/) in the R statistical envi-
ronment (http://cran.r-project.org/) (55).
Semiquantitative RT-PCR of human HTT
Equal amounts of RNA samples (1 μg) were treated with DNAse I 
(Ambion, Thermo Fisher Scientific), and 500 ng was reverse tran-
scribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche) 
according to the manufacturer’s protocol, and PCR was performed 
using the FastStart Taq DNA Polymerase, dNTPack (Roche). sCAGs 
were determined as previously described (9). Briefly, RNA samples 
were polyadenylated and annealed with a polyT adapter prior to retro-
transcription. Then, PCR amplification was performed using primers 
recognizing the adapter and sCAG.
PCR products were resolved by electrophoresis in 2% agarose gels 
and quantified using ImageJ software (NIH). The primers and PCR 
conditions used for HTT, β-actin, Gdx, and GFP cDNA (Figure 1, Fig-
ure 2, and Supplemental Figures 1–3, 9, and 10) are indicated in Sup-
plemental Table 2.
qPCR
Total RNA from mouse striatum was treated with DNAse I (Ambion, 
Thermo Fisher Scientific) and a retrotranscribed using Transcriptor 
First Strand cDNA Synthesis Kit (Roche) following the manufactur-
er’s instructions. cDNA was mixed with LightCycler 480 SYBR Green 
I and amplification performed in a LightCycler 480 Real-Time PCR 
System (Roche). For each gene, samples were analyzed in the same 
RT-PCR experiment and run in quadruplicate. Relative quantifica-
tion (RQ) was calculated with the 2ΔΔCt method (56) using Hprt or 
thick) were cut on a cryostat. For IHC, sections (processed as free 
floating) were washed 3 times in PBS, incubated for 30 minutes in 
a 50-mM NH4Cl solution, permeabilized, and blocked by incubat-
ing for 1 hour at room temperature with PBS containing 0.5% Triton 
X-100, 3% normal horse serum (Pierce Biotechnology, Thermo Fish-
er Scientific), and 0.2% BSA. After 3 washes (PBS with 0.5% Triton 
X-100), brain slices were incubated with anti–DARPP-32 antibodies 
(1:1,000; BD Biosciences) or anti–mutant HTT (1:150, EM48; EMD 
Millipore) overnight at 4°C. After primary antibody incubation, 
slices were washed 3 times (PBS with 0.5% Triton X-100) and then 
incubated for 2 hours at room temperature with the corresponding 
fluorescent secondary antibodies: Cy2 goat anti–guinea pig (1:500) 
and Cy3 goat anti-mouse (1:200) (both from Jackson ImmunoRe-
search). No signal was detected in controls incubated in the absence 
of primary antibodies. For nuclear staining, sections were incubated 
for 10 minutes at room temperature with Hoechst 33258 (1:4,000; 
Invitrogen, Thermo Fisher Scientific). DARPP-32 immunofluores-
cence was analyzed by confocal microscopy in coronal sections 
evenly spaced at 240 μm apart comprising rostral, middle, and 
caudal levels of the striatum (1.54 mm to –0.7 mm from bregma) as 
described elsewhere (50).
RNA foci detection by FISH in HD fibroblasts
RNA FISH was performed using a DNA/LNA probe (CTG)6–CA 
labeled at the 5′ end with Cy3 and following previously described pro-
cedures (6). Slides were mounted in Fluoroshield with DAPI medium 
(Sigma-Aldrich). Control experiments included RNAse A treatment 
(0.01 μg/ml for 1.5 hours at 37°C) prior to FISH staining. RNA foci 
were not detected in these conditions (data not shown). Cells were 
visualized using a Leica Confocal TCS SPE microscope.
Cell toxicity assays
Lactate dehydrogenase (LDH) released from dying cells was deter-
mined using the LDH assay (Cytotox 96; Promega) according to the 
manufacturer’s protocol. Absorbance was recorded at 490 nm, at dif-
ferent time points after transfection (see figure legends). LDH deter-
minations were performed in quadruplicate.
RNA isolation
The mouse dissected brain areas were placed immediately in QIAzol 
solution (QIAGEN), followed by RNA extraction with the miRNeasy 
kit (QIAGEN) as indicated by the manufacturer. RNA extraction from 
the neuronal cells or primary fibroblasts was also performed with 
mi RNeasy (QIAGEN) following the manufacturer’s instructions. 
Determinations of RNA quality and quantity were made with a 2100 
Bioanalyzer (Agilent Technologies) and an ND-1000 spectrophotom-
eter (Thermo Fisher Scientific), respectively. All RNA samples showed 
an RNA integrity number of 8 or higher.
sRNA fractions from DNAse I–treated total RNA were purified 
with the RNA Clean & Concentrator-5 Kit (Zymo Research) according 
to the manufacturer’s instructions.
Transcription of HTT-e1 and retrotranscription in the presence of LNA-ASOs
A plasmid containing a human HTT-e1 with 23 CAG repeats (9) was 
used PCR amplification of the HTT-e1 sequence and the upstream T7 
promoter. The PCR product was used as a template to synthesize a pure 
HTT-e1 RNA using the MAXIscript T7 Transcription Kit (Invitrogen, 
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Tbp as reference genes. RQ was calculated to compare all expression 
values normalized to the reference genes in WT animals injected 
with LNA-SCB, WT animals injected with LNA-CTG, R6/2 mice 
treated with LNA-SCB, and R6/2 mice treated with LNA-CTG (Sup-
plemental Figures 11–13 and Table 1). The primers used for qPCR and 
amplification efficiencies and amplification conditions are listed in 
Supplemental Table 3.
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Study approval
All procedures were performed in compliance with the NIH guide-
lines for the care and use of laboratory animals and approved by the 
IACUCs of the Universitat de Barcelona (99/01) and the Generalitat 
de Catalunya (99/1094).
 1.  A novel gene containing a trinucleotide repeat 
that is expanded unstable on Huntington’s 
disease chromosomes. The Huntington’s 
Disease Collaborative Research Group. Cell. 
1993;72(6):971–983.
 2. Cattaneo E, Zuccato C, Tartari M. Normal 
huntingtin function: an alternative approach 
to Huntington’s disease. Nat Rev Neurosci. 
2005;6(12):919–930.
 3. Takahashi T, Katada S, Onodera O. Polygluta-
mine diseases: Where does toxicity come from? 
What is toxicity? Where are we going? J Mol Cell 
Biol. 2010;2(4):180–191.
 4. Labbadia J, Morimoto RI. Huntington’s disease: 
underlying molecular mechanisms and emerging 
concepts. Trends Biochem Sci. 2013;38(8):378–385.
 5. Tsoi H, Lau TC, Tsang SY, Lau KF, Chan HY. 
CAG expansion induces nucleolar stress in 
polyglutamine diseases. Proc Natl Acad Sci U S A. 
2012;109(33):13428–13433.
 6. de Mezer M, Wojciechowska M, Napierala M, 
Sobczak K, Krzyzosiak WJ. Mutant CAG repeats 
of Huntingtin transcript fold into hairpins, form 
nuclear foci and are targets for RNA interference. 
Nucleic Acids Res. 2011;39(9):3852–3863.
 7. Mykowska A, Sobczak K, Wojciechowska M, Kozlo-
wski P, Krzyzosiak WJ. CAG repeats mimic CUG 
repeats in the misregulation of alternative splicing. 
Nucleic Acids Res. 2011;39(20):8938–8951.
 8. Galka-Marciniak P, Urbanek MO, Krzyzosiak WJ. 
Triplet repeats in transcripts: structural insights into 
RNA toxicity. Biol Chem. 2012;393(11):1299–1315.
 9. Bañez-Coronel M, et al. A pathogenic mechanism 
in Huntington’s disease involves small CAG-re-
peated RNAs with neurotoxic activity. PLoS 
Genet. 2012;8(2):e1002481.
 10. Jasinska A, et al. Structures of trinucleo-
tide repeats in human transcripts and their 
functional implications. Nucleic Acids Res. 
2003;31(19):5463–5468.
 11. Krzyzosiak WJ, Sobczak K, Wojciechowska M, 
Fiszer A, Mykowska A, Kozlowski P. Triplet 
repeat RNA structure and its role as pathogenic 
agent and therapeutic target. Nucleic Acids Res. 
2012;40(1):11–26.
 12. Nalavade R, Griesche N, Ryan DP, Hildebrand 
S, Krauss S. Mechanisms of RNA-induced tox-
icity in CAG repeat disorders. Cell Death Dis. 
2013;4:e752.
 13. Zu T, et al. Non-ATG-initiated translation direct-
ed by microsatellite expansions. Proc Natl Acad 
Sci U S A. 2011;108(1):260–265.
 14. Matsui M, Corey DR. Allele-selective inhibition 
of trinucleotide repeat genes. Drug Discov Today. 
2012;17(9-10):443–450.
 15. Fiszer A, Krzyzosiak WJ. Oligonucleotide-based 
strategies to combat polyglutamine diseases. 
Nucleic Acids Res. 2014;42(11):6787–6810.
 16. Hu J, Matsui M, Corey DR. Allele-selective inhi-
bition of mutant huntingtin by peptide nucleic 
acid-peptide conjugates, locked nucleic acid, 
and small interfering RNA. Ann N Y Acad Sci. 
2009;1175:24–31.
 17. Gagnon KT, et al. Allele-selective inhibition of 
mutant huntingtin expression with antisense 
oligonucleotides targeting the expanded CAG 
repeat. Biochemistry. 2010;49(47):10166–10178.
 18. Fiszer A, et al. An evaluation of oligonucle-
otide-based therapeutic strategies for polyQ 
diseases. BMC Mol Biol. 2012;13:6.
 19. Gines S, Ivanova E, Seong IS, Saura CA, Mac-
Donald ME. Enhanced Akt signaling is an early 
pro-survival response that reflects N-methyl- D-
aspartate receptor activation in Huntington’s 
disease knock-in striatal cells. J Biol Chem. 
2003;278(50):50514–50522.
 20. Nucifora FC, et al. Interference by hunting-
tin and atrophin-1 with cbp-mediated tran-
scription leading to cellular toxicity. Science. 
2001;291(5512):2423–2428.
 21. Luthi-Carter R, et al. Decreased expression 
of striatal signaling genes in a mouse model 
of Huntington’s disease. Hum Mol Genet. 
2000;9(9):1259–1271.
 22. Sun Z, Del Mar N, Meade C, Goldowitz D, Reiner 
A. Differential changes in striatal projection neu-
rons in R6/2 transgenic mice for Huntington’s 
disease. Neurobiol Dis. 2002;11(3):369–385.
 23. Torres-Peraza JF, Giralt A, García-Martínez JM, 
Pedrosa E, Canals JM, Alberch J. Disruption of 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 3 3 0 jci.org   Volume 126   Number 11   November 2016
striatal glutamatergic transmission induced by 
mutant huntingtin involves remodeling of both 
postsynaptic density and NMDA receptor signal-
ing. Neurobiol Dis. 2008;29(3):409–421.
 24. Saavedra A, et al. PH domain leucine-rich repeat 
protein phosphatase 1 contributes to maintain 
the activation of the PI3K/Akt pro-survival path-
way in Huntington’s disease striatum. Cell Death 
Differ. 2010;17(2):324–335.
 25. Saavedra A, et al. Striatal-enriched protein 
tyrosine phosphatase expression and activity in 
Huntington’s disease: a STEP in the resistance to 
excitotoxicity. J Neurosci. 2011;31(22):8150–8162.
 26. Krol J, Fiszer A, Mykowska A, Sobczak K, de 
Mezer M, Krzyzosiak WJ. Ribonuclease dicer 
cleaves triplet repeat hairpins into shorter 
repeats that silence specific targets. Mol Cell. 
2007;25(4):575–586.
 27. Lawlor KT, et al. Double-stranded RNA is patho-
genic in Drosophila models of expanded repeat 
neurodegenerative diseases. Hum Mol Genet. 
2011;20(19):3757–3768.
 28. Tsoi H, Chan HY. Expression of expanded CAG 
transcripts triggers nucleolar stress in Hunting-
ton’s disease. Cerebellum. 2013;12(3):310–312.
 29. Hu J, et al. Allele-specific silencing of mutant 
huntingtin and ataxin-3 genes by targeting 
expanded CAG repeats in mRNAs. Nat Biotech-
nol. 2009;27(5):478–484.
 30. Gagnon KT, et al. Antisense and antigene inhibi-
tion of gene expression by cell-permeable oligo-
nucleotide-oligospermine conjugates. J Am Chem 
Soc. 2011;133(22):8404–8407.
 31. Boudreau RL, et al. Nonallele-specific silencing 
of mutant and wild-type huntingtin demon-
strates therapeutic efficacy in Huntington’s dis-
ease mice. Mol Ther. 2009;17(6):1053–1063.
 32. Drouet V, et al. Sustained effects of nonal-
lele-specific Huntingtin silencing. Ann Neurol. 
2009;65(3):276–285.
 33. Harper SQ, et al. RNA interference improves 
motor and neuropathological abnormalities in 
a Huntington’s disease mouse model. Proc Natl 
Acad Sci U S A. 2005;102(16):5820–5825.
 34. DiFiglia M, et al. Therapeutic silencing of mutant 
huntingtin with siRNA attenuates striatal and cor-
tical neuropathology and behavioral deficits. Proc 
Natl Acad Sci U S A. 2007;104(43):17204–17209.
 35. Kordasiewicz HB, et al. Sustained therapeutic 
reversal of Huntington’s disease by transient 
repression of huntingtin synthesis. Neuron. 
2012;74(6):1031–1044.
 36. Sun X, et al. Phosphorodiamidate morpholino 
oligomers suppress mutant huntingtin expres-
sion and attenuate neurotoxicity. Hum Mol Genet. 
2014;23(23):6302–6317.
 37. Mangiarini L, et al. Exon 1 of the HD gene with 
an expanded CAG repeat is sufficient to cause a 
progressive neurological phenotype in transgenic 
mice. Cell. 1996;87(3):493–506.
 38. Bennett CF, Swayze EE. RNA targeting therapeu-
tics: molecular mechanisms of antisense oligo-
nucleotides as a therapeutic platform. Annu Rev 
Pharmacol Toxicol. 2010;50:259–293.
 39. Wojtkowiak-Szlachcic A, et al. Short anti-
sense-locked nucleic acids (all-LNAs) correct 
alternative splicing abnormalities in myotonic dys-
trophy. Nucleic Acids Res. 2015;43(6):3318–3331.
 40. Bañez-Coronel M, et al. RAN Translation in Hun-
tington Disease. Neuron. 2015;88(4):667–677.
 41. Dragatsis I, et al. CAG repeat lengths ≥335 
attenuate the phenotype in the R6/2 Hunting-
ton’s disease transgenic mouse. Neurobiol Dis. 
2009;33(3):315–330.
 42. Møllersen L, Rowe AD, Larsen E, Rognes T, Klun-
gland A. Continuous and periodic expansion of 
CAG repeats in Huntington’s disease R6/1 mice. 
PLoS Genet. 2010;6(12):e1001242.
 43. Morton AJ, et al. Paradoxical delay in the 
onset of disease caused by super-long CAG 
repeat expansions in R6/2 mice. Neurobiol Dis. 
2009;33(3):331–341.
 44. Giralt A, Saavedra A, Carretón O, Xifró X, 
Alberch J, Pérez-Navarro E. Increased PKA sig-
naling disrupts recognition memory and spatial 
memory: role in Huntington’s disease. Hum Mol 
Genet. 2011;20(21):4232–4247.
 45. The Huntington’s Disease Collaborative 
Research Group. A novel gene containing a 
trinucleotide repeat that is expanded unstable 
on Huntington’s disease chromosomes. Cell. 
1993;72(6):971–983.
 46. Giralt A, Carretón O, Lao-Peregrin C, Martín 
ED, Alberch J. Conditional BDNF release under 
pathological conditions improves Huntington’s 
disease pathology by delaying neuronal dysfunc-
tion. Mol Neurodegener. 2011;6(1):71.
 47. Ferrante RJ, et al. Therapeutic effects of coen-
zyme Q10 and remacemide in transgenic mouse 
models of Huntington’s disease. J Neurosci. 
2002;22(5):1592–1599.
 48. Rué L, López-Soop G, Gelpi E, Martínez-Vicente 
M, Alberch J, Pérez-Navarro E. Brain region- and 
age-dependent dysregulation of p62 and NBR1 in 
a mouse model of Huntington’s disease. Neurobi-
ol Dis. 2013;52:219–228.
 49. Watson JD, Varley JG, Tomlin SJ, Medbak S, Rees 
LH, Hinds CJ. Biochemical characterization of 
circulating Met-enkephalins in canine endotoxin 
shock. J Endocrinol. 1986;111(2):329–334.
 50. Brito V, Puigdellívol M, Giralt A, del Toro D, 
Alberch J, Ginés S. Imbalance of p75(NTR)/
TrkB protein expression in Huntington’s disease: 
implication for neuroprotective therapies. Cell 
Death Dis. 2013;4:e595.
 51. Ritchie ME, et al. A comparison of background 
correction methods for two-colour microarrays. 
Bioinformatics. 2007;23(20):2700–2707.
 52. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A 
comparison of normalization methods for high 
density oligonucleotide array data based on vari-
ance and bias. Bioinformatics. 2003;19(2):185–193.
 53. Smyth GK. Linear models and empirical bayes 
methods for assessing differential expression in 
microarray experiments. Stat Appl Genet Mol Biol. 
2004;3:Article3.
 54. Benjamini Y,  Hochberg Y. Controlling the false dis-
covery rate: a practical and powerful approach  
to multiple testing. J R Stat Soc Series B Stat Meth-
odol. 1995;57(1), 289-300. http://www.jstor.org/
stable/2346101. Accessed September 29, 2016.
 55. Gentleman RC, et al. Bioconductor: open soft-
ware development for computational biology and 
bioinformatics. Genome Biol. 2004;5(10):R80.
 56. Livak KJ, Schmittgen TD. Analysis of relative 
gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method. Meth-
ods. 2001;25(4):402–408.
 57. Steibel JP, Poletto R, Coussens PM, Rosa GJ. A 
powerful and flexible linear mixed model frame-
work for the analysis of relative quantification 
RT-PCR data. Genomics. 2009;94(2):146–152.
 58. Miñones-Moyano E, et al. MicroRNA profiling 
of Parkinson’s disease brains identifies early 
downregulation of miR-34b/c which modu-
late mitochondrial function. Hum Mol Genet. 
2011;20(15):3067–3078.
